CADM1 and cancer: Functional experiments, as well as single-cell RNA sequencing (scRNA-seq), further indicated that TMZ treatment resulted in cellular heterogeneity which induced quiescent cancer stem cells (CSCs), labeled by NES+/SOX2+/CADM1+ and acting as a major contributor of TMZ resistance.